Melanotan-1 vs MT-1: Same Peptide, Different Name

The peptide community generates its own mythology. And one of the most persistent is the idea that melanotan-1 and MT-1 are different compounds with distinct effects or potency levels. They're not. Both terms refer to the same molecule: afamelanotide, a 13-amino-acid peptide sequence first synthesized at the University of Arizona in 1984 as part of research into photoprotection and erythropoietic protoporphyria (EPP). The 'MT-1' designation is simply shorthand. A lab abbreviation that stuck as the compound moved from preclinical work into human trials.

Our team has guided research institutions through peptide sourcing for over a decade. The naming confusion matters because it creates unnecessary hesitation during procurement. Researchers assume they need to choose between variants when they're ordering the same exact sequence.

What's the difference between melanotan-1 and MT-1?

There is no difference between melanotan-1 and MT-1. Both names refer to afamelanotide (C78H111N21O19), a synthetic analog of alpha-melanocyte-stimulating hormone. The peptide contains the same 13-amino-acid sequence (Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) regardless of nomenclature. MT-1 is simply an abbreviated designation used in early research protocols and carried forward into commercial naming conventions.

Direct Answer: Why Two Names for One Peptide

The dual naming reflects how peptides move from academic research into broader use. 'Melanotan-1' describes the compound's mechanism and development lineage. It's the first-generation synthetic melanocortin. 'MT-1' is the research shorthand that appeared in lab notebooks and early publications. When the peptide received regulatory approval as Scenesse for erythropoietic protoporphyria treatment in the European Union and Australia, the pharmaceutical name 'afamelanotide' became the official designation. All three terms. Melanotan-1, MT-1, and afamelanotide. Describe the identical molecular structure.

This article covers the peptide's mechanism of action, how it differs from melanotan-2 (MT-2), proper reconstitution protocols for research use, and what storage conditions are non-negotiable for maintaining peptide integrity.

How Melanotan-1/MT-1 Works at the Receptor Level

Afamelanotide functions as a melanocortin-1 receptor (MC1R) agonist. It binds to MC1R on melanocytes in the skin and activates the cyclic AMP (cAMP) pathway that triggers eumelanin synthesis. Eumelanin is the brown-black pigment responsible for photoprotection; its production increases melanin density in the epidermis without requiring UV exposure. This is the core distinction between synthetic melanocortins and natural tanning: the peptide initiates pigment production through direct receptor activation, bypassing the DNA-damaging UV radiation that normally stimulates melanogenesis.

The peptide's selectivity matters. Melanotan-1 demonstrates 1,000-fold selectivity for MC1R over MC3R and MC4R. The melanocortin receptors involved in appetite regulation and sexual function. This selectivity profile minimizes off-target effects compared to melanotan-2, which exhibits broader receptor binding and produces side effects (nausea, spontaneous erections, appetite suppression) absent in MT-1 protocols. Research published in the Journal of Medicinal Chemistry demonstrated that afamelanotide's binding affinity for MC1R is approximately 10 nM, with negligible MC4R activation at therapeutic doses.

In our experience working with research-grade peptide supply chains, MT-1's receptor selectivity is why institutions studying photoprotection or pigmentation disorders choose it over MT-2. The pharmacological profile is cleaner and the data interpretation is less confounded by appetite or cardiovascular variables.

Melanotan-1 vs Melanotan-2: The Real Distinction That Matters

The confusion between MT-1 and MT-2 is understandable. Both are synthetic melanocortins developed from the same precursor research. But their pharmacology diverges significantly. Melanotan-2 (MT-2) is a cyclic heptapeptide analog with a disulfide bridge, structurally modified to increase potency and reduce peptide length. That structural change produces broader melanocortin receptor binding: MT-2 activates MC1R, MC3R, MC4R, and MC5R with nearly equal affinity, which is why users report appetite suppression, libido changes, and nausea alongside pigmentation.

Melanotan-1 is a linear 13-amino-acid sequence with high MC1R selectivity. It does not produce the central nervous system effects associated with MT-2 because it does not cross the blood-brain barrier efficiently and does not activate MC4R (the receptor implicated in appetite and sexual arousal pathways). Clinical trials of afamelanotide for EPP. A condition requiring months of continuous dosing. Report minimal adverse events beyond injection-site reactions and mild nausea in fewer than 5% of participants. MT-2 anecdotal reports consistently describe nausea rates above 30% and spontaneous erections in male users.

Dosing further differentiates them. MT-1 therapeutic protocols use 16 mg subcutaneous implants that release 1 mg per day over 60 days (Scenesse formulation), or daily injections of 0.5–1.0 mg for research applications. MT-2 dosing is typically 0.25–1.0 mg per injection due to higher potency per milligram. The peptides are not interchangeable. Substituting one for the other in a research protocol would alter both the melanogenic effect and the side effect profile.

Melanotan-1/MT-1: Comparison Overview

Key Takeaways

• Melanotan-1 and MT-1 are identical. Both terms refer to afamelanotide, a 13-amino-acid synthetic peptide that activates melanocortin-1 receptors to stimulate eumelanin production.
• The peptide demonstrates 1,000-fold selectivity for MC1R over MC4R, which is why it produces pigmentation without appetite suppression or sexual side effects seen with melanotan-2.
• Afamelanotide is the only synthetic melanocortin approved for clinical use. Marketed as Scenesse for erythropoietic protoporphyria in the EU and Australia since 2014.
• Reconstituted melanotan-1 must be stored at 2–8°C and used within 28 days; lyophilized powder stored at −20°C remains stable for 24+ months.
• MT-1 requires higher absolute doses than MT-2 (typically 0.5–1.0 mg vs 0.25–0.5 mg) but produces fewer off-target effects due to its receptor selectivity profile.
• The peptide does not cross the blood-brain barrier efficiently, which limits central nervous system effects and makes adverse event profiles more predictable in research protocols.

What If: Melanotan-1/MT-1 Scenarios

What If the Peptide I Received Is Labeled 'MT-1' Instead of 'Melanotan-1'?

Use it. The labeling difference reflects supplier naming conventions, not molecular content. Both terms describe afamelanotide (C78H111N21O19), and reputable suppliers use them interchangeably. Verify purity through third-party certificate of analysis (COA) showing >98% purity by HPLC, which is standard for research-grade peptides. Our team has sourced MT-1 under both labels from FDA-registered 503B facilities. The molecular structure is identical.

What If I Accidentally Ordered Melanotan-2 Thinking It Was the Same as MT-1?

Do not use them interchangeably in the same protocol. Melanotan-2's broader receptor binding produces different pharmacological effects (appetite suppression, nausea, cardiovascular changes) that will confound research data if substituted mid-study. MT-2 also requires different dosing. Using MT-1 dosing guidelines (0.5–1.0 mg) with MT-2 would produce excessive receptor saturation and amplified side effects. If the substitution hasn't occurred yet, return or store the MT-2 separately and order MT-1 specifically by CAS number (75921-69-6) to avoid future confusion.

What If Reconstituted MT-1 Looks Cloudy or Has Visible Particles?

Discard it immediately. Cloudiness or particulate matter indicates protein aggregation or contamination. Both render the peptide unusable. Aggregated peptides lose bioactivity because the tertiary structure required for receptor binding has denatured. Contamination introduces variables that invalidate research results. Proper reconstitution (injecting bacteriostatic water slowly down the vial wall, allowing the lyophilized cake to dissolve without agitation) should produce a clear, colorless solution. If cloudiness appears after storage, temperature excursion above 8°C is the likely cause.

The Unvarnished Truth About Melanotan-1 vs MT-1 Nomenclature

Here's the honest answer: the difference is marketing and historical carryover. Nothing more. Peptide suppliers use 'MT-1' because it's shorter and customers searching for it assume it's distinct from 'melanotan-1,' which creates two product listings for the same molecule. Researchers new to melanocortin peptides waste time cross-referencing CAS numbers and amino-acid sequences to confirm they're identical when a single glance at the molecular formula (C78H111N21O19) would settle it. The confusion benefits no one except vendors who can charge different prices for differently labeled vials of the same compound.

The regulatory name is afamelanotide. That's the only designation with legal meaning. If you're citing peptide use in publications, grants, or regulatory submissions, use 'afamelanotide' and include the CAS number. If you're ordering for research, specify the CAS number (75921-69-6) regardless of what the supplier calls it. Anything else is noise.

Reconstitution and Storage: The Protocol That Actually Matters

Melanotan-1 arrives as a lyophilized powder, typically in 10 mg vials. Reconstitution requires bacteriostatic water. Not sterile water, not saline. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth in multi-dose vials and extends usable life to 28 days under refrigeration. Sterile water supports bacterial proliferation after the first needle puncture, making it unsafe for protocols requiring multiple draws over weeks.

Reconstitution steps: (1) Inject bacteriostatic water slowly down the inside wall of the vial, not directly onto the lyophilized cake. Direct injection causes foaming and peptide denaturation. (2) Allow the powder to dissolve passively for 2–3 minutes. Do not shake or vortex. (3) Gently swirl if undissolved material remains after 5 minutes. The final solution should be clear and colorless.

Storage rules are non-negotiable. Unreconstituted lyophilized MT-1 must be stored at −20°C and remains stable for 24+ months. Once reconstituted, refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 8°C. Even briefly. Initiates irreversible protein denaturation. Frozen reconstituted peptide loses bioactivity upon thawing because ice crystal formation disrupts peptide structure. Room-temperature storage reduces potency by approximately 50% within 7 days.

In our experience supplying peptides to academic and commercial research labs, storage protocol violations are the single most common cause of 'non-responsive' results. A peptide stored incorrectly isn't slightly less effective. It's functionally inert. Detailed protocols for handling peptide reconstitution appear in our technical documentation, which we've refined across hundreds of institutional accounts.

The naming might be inconsistent, but the chemistry is not. Melanotan-1 and MT-1 are the same peptide with the same sequence, the same receptor selectivity, and the same storage requirements. The distinction that actually matters isn't in the label. It's whether the vial was kept cold and reconstituted correctly.